home / stock / vrtx / vrtx articles

VRTX Articles, Vertex Pharmaceuticals Incorporated - From 04/09/24

Stock Information
Company Name: Vertex Pharmaceuticals Incorporated
Stock Symbol: VRTX
Market: NASDAQ
Website: vrtx.com
Menu
VRTX VRTX Quote VRTX Short VRTX News VRTX Articles VRTX Message Board
Get VRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse' | Benzinga

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over Penumbra, Inc. (NYSE: PE...
If You Invested $100 In This Stock 20 Years Ago, You Would Have $4,400 Today | Benzinga

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 12.82% on an annualized basis producing an average annua...

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years | Benzinga

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.13% on an annualized basis producing an average annual...

$100 Invested In This Stock 15 Years Ago Would Be Worth $1,500 Today | Benzinga

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 6.1% on an annualized basis producing an average annual ...
Median Drug Prices For Rare Diseases Hit $300K In 2023, Report Highlights Lack of Clear Rationale Behind Escalating Drug Prices | Benzinga

In a significant trend, pharmaceutical companies in the U.S. introduced new drugs last year at prices 35% higher than in 2022, notably attributed t...

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today | Benzinga

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 5.51% on an annualized basis producing an average annual ...

Vertex's Next-Generation Cystic Fibrosis Program Shows Efficacy With Reduced Burden, Provides Growth Opportunity: Goldman Sachs | Benzinga

Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanz...
Vertex Pharmaceuticals' Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients | Benzinga

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released results from its once-daily vanzacaftor/tezacaftor/deutivacaftor (vanza triple) pro...

Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday | Benzinga

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...

Vertex Pharmaceuticals Gears Up For Q4 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | Benzinga

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is expected to release earnings results for its fourth quarter, after the closing bell on Feb. 5...
Previous 10 Next 10